港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

中慧生物-B

40.880

-2.320-5.37%

成交量：17.98万

成交额：748.53万

市值：160.84亿

市盈率：-52.02

高：43.900

开：43.200

低：40.420

收：43.200

52周最高：59.600

52周最低：33.000

股本：3.93亿

香港流通股本：2.96亿

量比：1.02

换手率：0.06%

股息：- -

股息率：- -

每股收益(LYR):-0.786

净资产收益率：--

总资产收益率：--

市净率：437.01

市盈率(LYR):-52.02

市销率: 45.43

数据加载中...

总览公司新闻资讯公告

中慧生物-B大跌5.07% 四价流感病毒亚单位疫苗上市申请获批

港股异动 | 中慧生物-B(02627.HK)涨超3% 四价流感病毒亚单位疫苗上市申请获国家药监局批准

智通港股早知道 | 美联储褐皮书显示就业水平总体保持稳定美联储9月降息概率为96.6%

中慧生物-B(02627)：四价流感病毒亚单位疫苗的上市申请获国家药监局批准

中慧生物-B四价亚单位流感疫苗获得中国国家药监局批准

中慧生物2025 年中期业绩报告：商业化加速兑现研发管线梯次突破

智通财经网

中慧生物(02627.HK)2025 年中期业绩报告：商业化加速兑现研发管线梯次突破

中报收入同比大幅增长超900%，深挖中慧生物-B(02627)硬核创新技术背后“投资确定性”

港股异动 | 中慧生物-B(02627)收涨1.35% 中期收入同比激增逾9倍

中慧生物-B(02627)发布中期业绩收入7112.3万元同比大涨919.25%

【IPO前哨】天辰生物赴港：估值超20亿，研发烧钱何时休？

中慧生物-B08月26日获主力加仓213.9万元

高特佳投资企业中慧生物成功登陆港交所，核心疫苗产品加速全球化布局

中国资产全面爆发！港股打新最高涨近300%

老虎资讯综合

港股异动 | 中慧生物-B(02627)涨超7% 重组呼吸道合胞病毒疫苗IND申请中美双报获批

中慧生物-B(02627)：重组呼吸道合胞病毒疫苗(CHO细胞)(佐剂)的IND获中国CDE及美国FDA批准

港股IPO周报：港股18A打新浪潮回归！中慧生物-B、银诺医药-B上市首日大涨

异动解读 | 中慧生物-B股价盘中大跌5.13%，疑因大宗交易抛售

港股生物医药概念股强势拉升，中慧生物-B、北海康成-B涨超30%

老虎资讯综合

港股异动 | 中慧生物-B(02627.HK)再涨超20% 四价流感病毒亚单位疫苗入选商保创新药目录初审名单

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02627/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"中慧生物-B","latestPrice":40.88,"timestamp":1763366893781,"preClose":43.2,"halted":0,"volume":179800,"delay":0,"floatShares":296361845,"shares":393442600,"eps":-0.7858466390823721,"marketStatus":"未开盘","change":-2.32,"latestTime":"11-17 16:08:13","open":43.2,"high":43.9,"low":40.42,"amount":7485336,"amplitude":0.080556,"askPrice":41.1,"askSize":1600,"bidPrice":40.5,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-0.6816943896265432,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":43.2,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":1.019968232704777,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.785847,"volumeRatio":1.019968232704777,"shares":393442600,"dividePrice":0,"high":43.9,"amplitude":0.080556,"preClose":43.2,"low":40.42,"week52Low":33,"pbRate":"437.01","psRate":"45.43","week52High":59.6,"institutionHeld":0,"latestPrice":40.88,"committee":-0.454545,"eps":-0.7858466390823721,"divideRate":0,"volume":179800,"delay":0,"ttmEps":-0.6816943896265432,"open":43.2,"prevYearClose":12.9,"prevWeekClose":43.2,"prevMonthClose":40.3,"prevQuarterClose":49.3,"fiveDayClose":40.5,"twentyDayClose":43.58,"sixtyDayClose":50},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2025-11-14","current":-59.977255,"percent":0.41791,"low":-83.59026,"twenty":-76.901535,"median":-66.692171,"eighty":-63.572329,"high":-18.07815,"avg":-68.020963,"sd":9.719392,"marketCap":16996720320},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-29","current":-64.920623,"twenty":-66.830053,"median":-65.395346,"eighty":-57.22288,"marketCap":20065572600},{"date":"2025-09-05","current":-62.716917,"twenty":-66.416243,"median":-63.912829,"eighty":-60.155426,"marketCap":19365244772},{"date":"2025-09-12","current":-62.655098,"twenty":-66.251138,"median":-63.08644,"eighty":-59.27469,"marketCap":19380982476},{"date":"2025-09-19","current":-81.048551,"twenty":-68.315951,"median":-63.912829,"eighty":-59.882299,"marketCap":19888523430},{"date":"2025-09-26","current":-77.095946,"twenty":-77.153546,"median":-65.395346,"eighty":-60.155426,"marketCap":18869507096},{"date":"2025-10-03","current":-76.784092,"twenty":-77.86406,"median":-66.074095,"eighty":-61.128611,"marketCap":18838031688},{"date":"2025-10-10","current":-75.450727,"twenty":-78.338288,"median":-66.623148,"eighty":-61.710077,"marketCap":18483933348},{"date":"2025-10-17","current":-70.044793,"twenty":-77.841467,"median":-68.315951,"eighty":-62.332762,"marketCap":17146228508},{"date":"2025-10-24","current":-70.694139,"twenty":-77.356453,"median":-69.86748,"eighty":-62.632094,"marketCap":17311474400},{"date":"2025-10-31","current":-64.652972,"twenty":-77.130506,"median":-68.586563,"eighty":-62.679826,"marketCap":15855736780},{"date":"2025-11-07","current":-65.014442,"twenty":-77.0495,"median":-67.012733,"eighty":-63.012535,"marketCap":15934425300},{"date":"2025-11-14","current":-69.152784,"twenty":-76.901535,"median":-66.692171,"eighty":-63.572329,"marketCap":16996720320}],"updateTime":1763378119907},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566989224","title":"中慧生物-B大跌5.07% 四价流感病毒亚单位疫苗上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2566989224","media":"港美通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566989224?lang=zh_cn&edition=fundamental","pubTime":"2025-09-10 10:18","pubTimestamp":1757470731,"startTime":"0","endTime":"0","summary":"消息面上，中慧生物-B近日宣布，中国国家药品监督管理局已批准集团针对6-35月龄人群的四价流感病毒亚单位疫苗的新药申请，该款疫苗为中国首款且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。这一增长主要归因于四价流感病毒亚单位疫苗的销售逐步增加，以及对收入的调整以校准2024年销售的估计退货。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910102012a71afbf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910102012a71afbf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2564492703","title":"港股异动 | 中慧生物-B(02627.HK)涨超3% 四价流感病毒亚单位疫苗上市申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2564492703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564492703?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 10:00","pubTimestamp":1756951209,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159646","02627","BK1161"],"gpt_icon":0},{"id":"2564107443","title":"智通港股早知道 | 美联储褐皮书显示就业水平总体保持稳定 美联储9月降息概率为96.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564107443","media":"智通财经","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564107443?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 07:30","pubTimestamp":1756942247,"startTime":"0","endTime":"0","summary":"美联储褐皮书显示就业水平总体保持稳定 美联储9月降息概率为96.6%美联储褐皮书指出，十一个辖区报告就业水平总体保持稳定或几无净变化，一个辖区出现温和下降。据CME“美联储观察”：美联储9月维持利率不变的概率为3.4%，降息25个基点的概率为96.6%。该变更将于 2025 年 9 月 19 日星期五收盘后生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SH","BK1161","BK4550","BK4559","YANG","BK4534","SPXU","09863","BK4581","BK4614","BK1152","02627","00315","IVV","SPY","UPRO","OEX",".SPX","09880","BK1613","BK4504","MESmain","SSO","BK4588","HSTECH","BK1536","BK1183","ESmain","HSCEI","OEF","BK4585","SDS","BK1119"],"gpt_icon":1},{"id":"2564308361","title":"中慧生物-B(02627)：四价流感病毒亚单位疫苗的上市申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2564308361","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564308361?lang=zh_cn&edition=fundamental","pubTime":"2025-09-03 17:36","pubTimestamp":1756892194,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，公司董事会欣然宣布，中国国家药品监督管理局已批准集团针对6-35月龄人群的四价流感病毒亚单位疫苗的新药申请。截至本公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。集团的产品包括但不限于，四价流感病毒亚单位疫苗及在研冻干人用狂犬病疫苗，以及其他在研疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","159646","BK1161"],"gpt_icon":0},{"id":"1135028630","title":"中慧生物-B四价亚单位流感疫苗获得中国国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1135028630","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135028630?lang=zh_cn&edition=fundamental","pubTime":"2025-09-03 17:35","pubTimestamp":1756892115,"startTime":"0","endTime":"0","summary":"中慧生物-B的四价亚单位流感疫苗申请获得中国国家药品监督管理局批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2563243000","title":"中慧生物2025 年中期业绩报告：商业化加速兑现 研发管线梯次突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2563243000","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563243000?lang=zh_cn&edition=fundamental","pubTime":"2025-08-29 12:51","pubTimestamp":1756443067,"startTime":"0","endTime":"0","summary":"财报显示，公司核心产品四价流感病毒亚单位疫苗——慧尔康欣 商业化成效显著，营收实现跨越式增长，期内亏损同比收窄，同时研发管线按计划推进，全球化布局逐步落地。数据显示，中慧生物上半年经营业绩呈现显著向好趋势。目前已完成I期临床并显示良好安全性特征。2024 年已获澳门注册证书，菲律宾注册程序顺利启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829125346a7031050&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829125346a7031050&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2563018889","title":"中慧生物(02627.HK)2025 年中期业绩报告：商业化加速兑现 研发管线梯次突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2563018889","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563018889?lang=zh_cn&edition=fundamental","pubTime":"2025-08-29 12:43","pubTimestamp":1756442584,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02627","159646","159837"],"gpt_icon":0},{"id":"2562613034","title":"中报收入同比大幅增长超900%，深挖中慧生物-B(02627)硬核创新技术背后“投资确定性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2562613034","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562613034?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 20:08","pubTimestamp":1756382938,"startTime":"0","endTime":"0","summary":"虽然近日出现技术性波动，但结合公司最新披露的2025年中期业绩来看，收入同比大增超900%之后，其股价与市值在后续仍有巨大的持续走高空间。8月28日，中慧生物公布了其2025年中期业绩。报告期内，中慧生物实现收入7112.3万元，同比大幅增长919.25%。今年上半年收入大增超900%，说明中慧生物当前的创新疫苗开发与商业化运营模式正趋于成熟。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2562035502","title":"港股异动 | 中慧生物-B(02627)收涨1.35% 中期收入同比激增逾9倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2562035502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562035502?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 18:46","pubTimestamp":1756378007,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月28日，中慧生物-B在尾盘表现活跃，股价迅速拉升。截至收盘，该股涨1.35%，报52.5港元。当日盘后，中慧生物发布截至2025年6月30日止6个月中期业绩。中慧生物是一家总部位于中国的疫苗公司，致力于创新疫苗及采用新技术方法的传统疫苗的研发、制造及商业化。公司所有的疫苗产品及在研产品目前或预计于中国被归类为第二类疫苗。截至2025年6月30日，公司已成功从国家药监局获得九项在研疫苗的IND批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2562081894","title":"中慧生物-B(02627)发布中期业绩 收入7112.3万元 同比大涨919.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562081894","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562081894?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 16:49","pubTimestamp":1756370989,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布截至2025年6月30日止6个月中期业绩，集团收入人民币7112.3万元，同比增长919.25%;毛利6078.1万元;研发开支9884.8万元。公司成立于2015年，是一家总部位于中国的疫苗公司，致力于创新疫苗及采用新技术方法的传统疫苗的研发、制造及商业化。公司所有的疫苗产品及在研产品目前或预计于中国被归类为第二类疫苗。因此，截至2025年6月30日，公司已成功从国家药监局获得九项在研疫苗的IND批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"中慧生物-B(02627)发布中期业绩 收入7112.3万元 同比大涨919.25%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK1161"],"gpt_icon":1},{"id":"2562218467","title":"【IPO前哨】天辰生物赴港：估值超20亿，研发烧钱何时休？","url":"https://stock-news.laohu8.com/highlight/detail?id=2562218467","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562218467?lang=zh_cn&edition=fundamental","pubTime":"2025-08-27 15:23","pubTimestamp":1756279396,"startTime":"0","endTime":"0","summary":"今年以来，包括药捷安康-B（02617.HK）、维立志博-B（09887.HK）、中慧生物-B（02627.HK）、银诺医药-B（02591.HK）在内的众多生物科技企业通过第18A章登陆了港股市场，其中一些生物科技股在上市后有着非常亮眼的表现。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202508_1/a2dd3e09-1100-4ccc-82d8-cbdc3f3e7b19.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202508_1/a2dd3e09-1100-4ccc-82d8-cbdc3f3e7b19.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68aeb264230829534078cedd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["AR","02617","02627","09887","BK4213","02591","BK1161"],"gpt_icon":0},{"id":"2562532677","title":"中慧生物-B08月26日获主力加仓213.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562532677","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562532677?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 16:15","pubTimestamp":1756196156,"startTime":"0","endTime":"0","summary":"08月26日, 中慧生物-B股价涨1.71%，报收53.50元，成交金额2691.5万元，换手率0.17%，振幅4.85%，量比0.94。中慧生物-B今日主力资金净流入213.9万元，连续4日净流入，上一交易日主力净流入292.8万元。该股近5个交易日上涨3.78%，主力资金累计净流入462.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出581.0万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250826171237a49fb7ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250826171237a49fb7ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2562753211","title":"高特佳投资企业中慧生物成功登陆港交所，核心疫苗产品加速全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2562753211","media":"中华网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562753211?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 15:00","pubTimestamp":1756191603,"startTime":"0","endTime":"0","summary":"高特佳投资副总经理于建林表示：“中慧生物是国内创新疫苗领域的代表性企业，其核心产品‘慧尔康欣’是国内获批的首款且唯一一款四价流感病毒亚单位疫苗，技术处于国内领先水平。本次成功IPO，相信将把公司发展推向高速通道，进一步瞄准国际趋势，践行‘让中国用上全球创新疫苗，让世界用上中国优质疫苗’的企业愿景。”中慧生物始终致力于创新疫苗及采用新技术方法的传统疫苗的研发、制造及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082615070994fd5ce8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082615070994fd5ce8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1141757368","title":"中国资产全面爆发！港股打新最高涨近300%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141757368","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141757368?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 11:05","pubTimestamp":1755572712,"startTime":"0","endTime":"0","summary":"8月19日，中国资产全面爆发，A股沪指创近10年新高！港股IPO持续势如破竹，7月以来上市12支，首日10支收涨，2支收跌，胜率高达83.33%！累计一手收益可达15,367港元。📢 双登股份（06960）正在火热申购中🔥🚩 申购方式：【老虎国际App】-【持仓】-【IPO】✨ 老虎打新优势：✅ 现金申购0手续费，融资申购0孖展利息✅ 10倍杠杆，额度充足✅ 支持暗盘交易，快人一步抢占先机✅ TOP科技券商，安全可靠","market":"hk","thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"中国资产全面爆发！港股打新最高涨近300%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","02627","06960","09887"],"gpt_icon":0},{"id":"2560597557","title":"港股异动 | 中慧生物-B(02627)涨超7% 重组呼吸道合胞病毒疫苗IND申请中美双报获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2560597557","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560597557?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 09:45","pubTimestamp":1755481551,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中慧生物-B涨超7%，截至发稿，涨7.25%，报50.6港元，成交额1364.46万港元。消息面上，中慧生物公告，集团自主研发的重组呼吸道合胞病毒疫苗(佐剂)的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。公告指出，集团的重组呼吸道合胞病毒疫苗(佐剂)利用CHO细胞研制而成，可表达经修饰的pre-F蛋白。集团经广泛筛选获得了能够稳定表达pre-F蛋白的高产量单克隆细胞系。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"683842b7a5459c08a27a9a79e085b6a5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","02627"],"gpt_icon":0},{"id":"2560922523","title":"中慧生物-B(02627)：重组呼吸道合胞病毒疫苗(CHO细胞)(佐剂)的IND获中国CDE及美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2560922523","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560922523?lang=zh_cn&edition=fundamental","pubTime":"2025-08-17 19:26","pubTimestamp":1755429967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，集团自主研发的重组呼吸道合胞病毒疫苗(佐剂)的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。呼吸道合胞病毒作为一种高传染性RNA病毒，是导致婴儿、老年人和免疫功能不全者呼吸道感染的重要病原体之一。严重病例可危及生命。集团的重组呼吸道合胞病毒疫苗(佐剂)利用CHO细胞研制而成，可表达经修饰的pre-F蛋白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","CDE","LU1223082519.USD","BK4017","LU1223083913.SGD","02627","159646"],"gpt_icon":1},{"id":"2560924481","title":"港股IPO周报：港股18A打新浪潮回归！中慧生物-B、银诺医药-B上市首日大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2560924481","media":"活报告","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560924481?lang=zh_cn&edition=fundamental","pubTime":"2025-08-17 17:00","pubTimestamp":1755421200,"startTime":"0","endTime":"0","summary":"最近一周，两家18A中慧生物-B、银诺医药-B正式上市，首日表现相当亮眼，分别涨157.98%、206.48%，今年港股18A生物科技公司IPO赚钱效应显著，打新热潮强势回归。中慧生物-B上市首日股价大幅高开156%，早盘一度冲高至170%，而后持续于高位震荡，最终收盘涨157.98%，全天成交近900万股，成交额约2.98亿港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-08-17/doc-infmhrpc0843581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02627","BK4614","HSTECH","YANG","HSCEI","02591"],"gpt_icon":1},{"id":"1111748033","title":"异动解读 | 中慧生物-B股价盘中大跌5.13%，疑因大宗交易抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1111748033","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111748033?lang=zh_cn&edition=fundamental","pubTime":"2025-08-14 09:47","pubTimestamp":1755136058,"startTime":"0","endTime":"0","summary":"周四盘中，港股中慧生物-B（02627）股价出现大幅下跌，跌幅高达5.13%，引发市场关注。\n\n根据市场信息，该股在上午9时左右出现一笔大宗交易，卖出量为60万股，成交价为52.2港元，涉及资金达3132万港元。这笔大额抛售可能是导致股价下跌的主要原因，反映出部分大型投资者可能正在调整持仓或对公司未来发展持谨慎态度。\n\n截至目前，中慧生物-B今日的最高价和最低价均为52.2港元，总成交量达110万股，成交金额约5742万港元。这一大宗交易占据了当日总成交量的超过一半，显示出其对股价走势的重要影响。投资者应密切关注后续可能出现的公司公告或市场消息，以更好地理解此次股价变动的深层原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02627"],"gpt_icon":0},{"id":"1187244558","title":"港股生物医药概念股强势拉升，中慧生物-B、北海康成-B涨超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187244558","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187244558?lang=zh_cn&edition=fundamental","pubTime":"2025-08-13 10:01","pubTimestamp":1755050488,"startTime":"0","endTime":"0","summary":"8月13日，港股生物医药概念股强势拉升，$中慧生物-B(02627)$、$北海康成-B(01228)$涨超30%，$派格生物医药-B(02565)$涨近9%，$荃信生物-B(02509)$涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"eea96c2db952be4ad0141d428041d6b9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","01228","02565","BK1161","02509","09939"],"gpt_icon":0},{"id":"2559673494","title":"港股异动 | 中慧生物-B(02627.HK)再涨超20% 四价流感病毒亚单位疫苗入选商保创新药目录初审名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2559673494","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559673494?lang=zh_cn&edition=fundamental","pubTime":"2025-08-13 09:43","pubTimestamp":1755049381,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c87cae35bf9659f431e522bd02af029a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","159646","BK1161","159992","06978","02627"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":122,"code":"91000000","status":"200"}]}}